Publications

Export 37 results:
Sort by: Author Title Type [ Year (Desc)]
Submitted
Rabea, A. M., A. Shafik, B. Refky, E. Shash, K. A. Aziz, L. Kassem, N. Rashad, and O. Abdel-Rahman, The State of Lung Cancer in Egypt: Progress Is at Hand, , Submitted. Abstract
n/a
Azim, H. A., S. Dawood, N. El‐Saghir, L. Kassem, and H. A. Azim, Understanding the benefits and challenges of first‐line cyclin‐dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women, : John Wiley & Sons, Ltd (10.1111), Submitted. Abstract
n/a
2019
Choucair, A., T. H. Pham, S. Omarjee, J. Jacquemetton, L. Kassem, O. Trédan, J. Rambaud, E. Marangoni, L. Corbo, and I. Treilleux, The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer, , vol. 38, issue 21: Nature Publishing Group, pp. 4015, 2019. Abstract
n/a
Azim, H. A., L. Kassem, K. S. Shohdy, B. Eshaak, shady elia anis, and N. S. Kamal, Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin, , vol. 22, issue 1, pp. 141 - 148, 2019. Abstract
n/a
Montagna, G., D. Anderson, J. Bochenek-Cibor, I. Bozovic-Spasojevic, C. Campos, S. Cavallero, I. Durutovic, M. O. G. Cuadra, T. Irfan, and L. Joly, How to become a breast cancer specialist in 2018: The point of view of the second cohort of the Certificate of Competence in Breast Cancer (CCB2), , vol. 43: Churchill Livingstone, pp. 18 - 21, 2019. Abstract
n/a
Kassem, L., K. S. Shohdy, A. M. Abdel-Azeez, and H. Attia, Is the Fixed-Dose Intravenous Trastuzumab Policy Warranted in Limited-Resource Settings?, , vol. 5: American Society of Clinical Oncology, 2019. Abstract
n/a
Lattouf, H., L. Kassem, J. Jacquemetton, A. Choucair, C. Poulard, O. Trédan, L. Corbo, M. Diab‐Assaf, N. Hussein, and I. Treilleux, LKB1 regulates PRMT5 activity in breast cancer, , vol. 144, issue 3: John Wiley & Sons, Inc. Hoboken, USA, pp. 595 - 606, 2019. Abstract
n/a
2018
Kassem, L., P. Clézardin, and I. Treilleux, 97P RANK expression predicts long term outcome in early luminal breast cancer, , vol. 29, issue suppl_6: Oxford University Press, pp. mdy314 - 036, 2018. Abstract
n/a
Kassem, L., K. S. Shohdy, and O. Abdel-Rahman, Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy, , vol. 34, issue 5: Taylor & Francis, pp. 903 - 910, 2018. Abstract
n/a
Nougarede, A., N. Popgeorgiev, L. Kassem, S. Omarjee, S. Borel, I. Mikaelian, J. Lopez, R. Gadet, O. Marcillat, and I. Treilleux, Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10, , vol. 78, issue 6: American Association for Cancer Research, pp. 1404 - 1417, 2018. Abstract
n/a
Kassem, L., K. S. Shohdy, N. F. Makady, D. S. Salem, N. Ebrahim, and mostafa eldaly, Efficacy and Safety of Targeting Androgen Receptor in Advanced Breast Cancer: A Systematic Review, , vol. 14, pp. 1 - 11, 2018. Abstract
n/a
Kassem, L., K. S. Shohdy, S. Lasheen, O. Abdel-Rahman, and T. Bachelot, Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis, , vol. 25, issue 1: Springer Japan, pp. 17 - 27, 2018. Abstract
n/a
Shohdy, K. S., L. Kassem, and A. Mangalik, Is the Clinical Benefit Rate at Sixteen Weeks a Reliable End Point?, , vol. 36, issue 23: American Society of Clinical Oncology, pp. 2457 - 2458, 2018. Abstract
n/a
Azim, H. A., R. Abdel-Malek, and L. Kassem, Predicting brain metastasis in breast cancer patients: stage versus biology, , vol. 18, issue 2: Elsevier, pp. e187 - e195, 2018. Abstract
n/a
Kassem, L., K. S. Shohdy, S. Lasheen, O. Abdel-Rahman, A. Ali, and R. R. Abdel-Malek, Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review, : Elsevier, 2018. Abstract
n/a
Azim, H. A., A. Omar, H. Atef, H. Zawahry, M. K. Shaker, A. H. K. Abdelmaksoud, M. EzzElarab, O. Abdel-Rahman, M. Ismail, and L. Kassem, Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study), , vol. 5: Dove Press, pp. 109, 2018. Abstract
n/a
Azim, H. A., S. Lasheen, and L. Kassem, Treatment of HER 2‐positive early breast cancer: How to best balance efficacy and toxicity?, , vol. 24, issue 4, pp. 459 - 461, 2018. Abstract
n/a
2017
Kassem, L., M. Ismail, and H. A. Azim, Capecitabine and Vinorelbine Combination More Effective as the First Line Treatment of Advanced ER Positive Breast Cancer, , vol. 36: Elsevier, pp. S52, 2017. Abstract
n/a
Kassem, L., W. El Sheshtawy, S. Lasheen, M. Ismail, D. El Khishin, and H. Azim, Clinical and biological factors associated with higher rates of locoregional recurrences in Egyptian patients with early breast cancer, , vol. 32: Elsevier, pp. S128, 2017. Abstract
n/a
Lasheen, S., K. S. Shohdy, L. Kassem, and O. Abdel-Rahman, Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis, , vol. 17, issue 9: Taylor & Francis, pp. 851 - 856, 2017. Abstract
n/a
Shohdy, K. S., S. Lasheen, L. Kassem, and O. Abdel-Rahman, Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis, , vol. 8, issue 11: SAGE Publications Sage UK: London, England, pp. 337 - 347, 2017. Abstract
n/a
Shohdy, K., S. Lasheen, L. Kassem, and O. Abdel-Rahman, Gastrointestinal and Other Selected Adverse Effects of Cyclin-Dependent Kinase 4 and 6 Inhibitors in Breast Cancer Patients: A Systematic Review and Meta-Analysis, , vol. 36: Elsevier, pp. S58, 2017. Abstract
n/a
2016
Azim, H. A., L. Kassem, I. Treilleux, Q. Wang, M. A. E. Enein, S. E. Anis, and T. Bachelot, Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer, , vol. 9, issue 2: Elsevier, pp. 114 - 123, 2016. Abstract
n/a
Kassem, L., R. Abdel-Malek, D. Abd El Moneim, M. Ismail, and H. A. Azim, Impact of the biological subtype on the risk of developing brain metastasis in Egyptian breast cancer patients, , vol. 27, issue suppl_6: Oxford University Press, 2016. Abstract
n/a
Kassem, L., T. Bachelot, I. Treilleux, C. Zhang, and M. Le Romancer, The prognostic impact ofPI3K/AKT/mTORpathway aberrations on luminal breast cancer patients, : European Society for Medical Oncology, 2016. Abstract
n/a